You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Details for New Drug Application (NDA): 218110


✉ Email this page to a colleague

« Back to Dashboard


NDA 218110 describes PHENYLEPHRINE HYDROCHLORIDE, which is a drug marketed by Alcon, Caplin, Mankind Pharma, Paragon Bioteck, Accord Hlthcare, Amneal, Aspiro, Avet Lifesciences, Be Pharms, Endo Operations, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hainan Poly, Hikma, Meitheal, Provepharm Sas, Sagent Pharms Inc, Sandoz, and Genus, and is included in twenty-eight NDAs. It is available from thirty-three suppliers. There is one patent protecting this drug. Additional details are available on the PHENYLEPHRINE HYDROCHLORIDE profile page.

The generic ingredient in PHENYLEPHRINE HYDROCHLORIDE is phenylephrine hydrochloride; promethazine hydrochloride. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the phenylephrine hydrochloride; promethazine hydrochloride profile page.
Summary for 218110
Tradename:PHENYLEPHRINE HYDROCHLORIDE
Applicant:Aspiro
Ingredient:phenylephrine hydrochloride
Patents:0
Pharmacology for NDA: 218110
Mechanism of ActionAdrenergic alpha1-Agonists
Suppliers and Packaging for NDA: 218110
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PHENYLEPHRINE HYDROCHLORIDE phenylephrine hydrochloride SOLUTION;INTRAVENOUS 218110 ANDA Camber Pharmaceuticals, Inc. 31722-343 31722-343-32 10 VIAL, SINGLE-DOSE in 1 CARTON (31722-343-32) / 1 mL in 1 VIAL, SINGLE-DOSE
PHENYLEPHRINE HYDROCHLORIDE phenylephrine hydrochloride SOLUTION;INTRAVENOUS 218110 ANDA Camber Pharmaceuticals, Inc. 31722-343 31722-343-33 25 VIAL, SINGLE-DOSE in 1 CARTON (31722-343-33) / 1 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength10MG/ML (10MG/ML)
Approval Date:May 10, 2024TE:AP1RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength50MG/5ML (10MG/ML)
Approval Date:May 10, 2024TE:AP1RLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength100MG/10ML (10MG/ML)
Approval Date:May 10, 2024TE:AP1RLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.